136 related articles for article (PubMed ID: 16441230)
1. Targeting Aurora kinases in ovarian cancer.
Fu S; Hu W; Kavanagh JJ; Bast RC
Expert Opin Ther Targets; 2006 Feb; 10(1):77-85. PubMed ID: 16441230
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Ciccone MA; Maoz A; Casabar JK; Machida H; Mabuchi S; Matsuo K
Expert Opin Investig Drugs; 2016 Jul; 25(7):781-96. PubMed ID: 27101098
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
Fu S; Li Y; Huang J; Liu T; Hong Z; Chen A; Bast RC; Kavanagh JJ; Gershenson DM; Sood AK; Hu W
Cancer Biol Ther; 2012 Sep; 13(11):1034-41. PubMed ID: 22895067
[TBL] [Abstract][Full Text] [Related]
4. Aurora A and B kinases--targets of novel anticancer drugs.
Libertini S; Abagnale A; Passaro C; Botta G; Portella G
Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):219-41. PubMed ID: 20524930
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients.
Chen YJ; Chen CM; Twu NF; Yen MS; Lai CR; Wu HH; Wang PH; Yuan CC
Virchows Arch; 2009 Nov; 455(5):431-40. PubMed ID: 19838728
[TBL] [Abstract][Full Text] [Related]
6. Aurora B: a new prognostic marker and therapeutic target in cancer.
Portella G; Passaro C; Chieffi P
Curr Med Chem; 2011; 18(4):482-96. PubMed ID: 21143115
[TBL] [Abstract][Full Text] [Related]
7. Targeting aurora kinases in cancer treatment.
Kelly KR; Ecsedy J; Mahalingam D; Nawrocki ST; Padmanabhan S; Giles FJ; Carew JS
Curr Drug Targets; 2011 Dec; 12(14):2067-78. PubMed ID: 21777198
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
9. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
10. Update on aurora kinase inhibitors in gynecologic malignancies.
Tao X; Chon HS; Fu S; Kavanagh JJ; Hu W
Recent Pat Anticancer Drug Discov; 2008 Nov; 3(3):162-77. PubMed ID: 18991785
[TBL] [Abstract][Full Text] [Related]
11. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
12. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinases in ovarian cancer.
Pérez-Fidalgo JA; Gambardella V; Pineda B; Burgues O; Piñero O; Cervantes A
ESMO Open; 2020 Oct; 5(5):e000718. PubMed ID: 33087400
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinases as an anti-cancer target.
Ikezoe T
Cancer Lett; 2008 Apr; 262(1):1-9. PubMed ID: 18294763
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinases as targets for cancer therapy.
Mountzios G; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
[TBL] [Abstract][Full Text] [Related]
17. Advances in Aurora kinase inhibitor patents.
Coumar MS; Cheung CH; Chang JY; Hsieh HP
Expert Opin Ther Pat; 2009 Mar; 19(3):321-56. PubMed ID: 19441907
[TBL] [Abstract][Full Text] [Related]
18. Emerging serine-threonine kinase inhibitors for treating ovarian cancer.
Maoz A; Ciccone MA; Matsuzaki S; Coleman RL; Matsuo K
Expert Opin Emerg Drugs; 2019 Dec; 24(4):239-253. PubMed ID: 31755325
[No Abstract] [Full Text] [Related]
19. Target validation and biomarker identification in oncology : the example of aurora kinases.
Colombo R; Moll J
Mol Diagn Ther; 2008; 12(2):71-6. PubMed ID: 18422371
[TBL] [Abstract][Full Text] [Related]
20. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
